Kyorin Pharmaceutical Co (TSE:4569) Long-Term Debt: 円20,444 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4569 Kyorin Pharmaceutical Co Ltd TSE:4569
74 GF Score
Price 円1,170.00
GF Value 円1,582.96
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Kyorin Pharmaceutical Co Long-Term Debt?

Kyorin Pharmaceutical Co TSE:4569 +0.69% 74 Long-Term Debt is 円20,444 Mil as of Mar. 2026. GuruFocus rates TSE:4569 with a GF Score™ of 74/100 and a GF Value™ of 円1,582.96 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Kyorin Pharmaceutical Co's Long-Term Debt for the quarter that ended in Mar. 2026 was 円20,444 Mil.

Kyorin Pharmaceutical Co's quarterly Long-Term Debt declined from Sep. 2025 (円20,135 Mil) to Dec. 2025 (円20,096 Mil) but then increased from Dec. 2025 (円20,096 Mil) to Mar. 2026 (円20,444 Mil).

Kyorin Pharmaceutical Co's annual Long-Term Debt increased from Mar. 2024 (円435 Mil) to Mar. 2025 (円20,235 Mil) and increased from Mar. 2025 (円20,235 Mil) to Mar. 2026 (円20,444 Mil).

Kyorin Pharmaceutical Co  (TSE:4569) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Kyorin Pharmaceutical Co Long-Term Debt Related Terms

Kyorin Pharmaceutical Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Kyorin Pharmaceutical Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyorin Pharmaceutical Co Long-Term Debt Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,836.00 10,636.00 435.00 20,235.00 20,444.00

Kyorin Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20,235.00 20,185.00 20,135.00 20,096.00 20,444.00
TSE:4569
74GF Score
Kyorin Pharmaceutical Co Ltd TSE:4569
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of 円20,444 Mil mean?
Kyorin Pharmaceutical Co (TSE:4569) has a Long-Term Debt of 円20,444 Mil as of Mar. 2026.
Is Kyorin Pharmaceutical Co's Long-Term Debt too high?
Kyorin Pharmaceutical Co's current Long-Term Debt is 円20,444 Mil. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Long-Term Debt compare to ZTS and UTHR?
Kyorin Pharmaceutical Co's Long-Term Debt of 円20,444 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Kyorin Pharmaceutical Co's current Long-Term Debt is 円20,444 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,582.96, compared to a current price of 円1,170.00 — trading 26.1% below its estimated fair value. The current Long-Term Debt is 円20,444 Mil. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Long-Term Debt is 円20,444 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?

Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued. The current stock price of 円1,170.00 is trading 26.1% below its estimated GF Value™ of 円1,582.96. GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4569:

  • Long-Term Debt: 円20,444 Mil
  • GF Value™: 円1,582.96 vs. price of 円1,170.00 (26.1% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyorin Pharmaceutical Co Business Description

Address 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score

Get the complete analysis for TSE:4569

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,170.00
Price
円1,582.96
GF Value